Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 6Phase 1/2 2Phase NA 1Phase 3 1

Status

Completed 117Unknown 23Terminated 23Recruiting 21Active not recruiting 18Not yet recruiting 7Withdrawn 5Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7Gastrointestinal 4Thoracic 3Other hematologic neoplasm 3Gynecologic 3Lymphoid 2Genitourinary 2Classical hematology 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other 1Myeloid 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Eyelid Squamous Cell Carcinoma 1

Interventions

cemiplimab 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Suspended × Sarcoma × Clear all
NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI)

Phase 3 Suspended
420 enrolled
DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡